MYRIAPOD®
NGS SYSTEM

Myriapod NGS-IL CFTR panel

Complexity made easy

diatech pharmacogenetics

diatech pharmacogenetics

Myriapod NGS-IL CFTR panel

Principle of the method: Myriapod NGS-IL CFTR panel CE IVD kit allows the detection of the variants of the CFTR gene correlated with the genetic predisposition to cystic fibrosis

Starting material: genomic DNA extracted from blood or dry blood spots

Target Genomic regions: all CFTR exons including 5'-3' UTRs, exon/intron junctions and several clinical relevant intronic regions 1, 12, 22 and 25

Intended use: CE IVD workflow from DNA to data analysis of CFTR gene whose alteration can be used for the diagnosis of cystic fibrosis



Features:

- **All in one**: screening based on CFTR2 database and complete CFTR gene sequencing in one kit
- **Easy to use**: single tube multiplex PCR
- **Minimum quantity of DNA needed**: 1-5 ng of DNA per sample
- Direct detection of the most frequent **CNVs**
- Determination of **poly T** and **TG** repeats
- Reagent for **dry blood spot extraction** included
- **Quality inside**: positive control with orthogonally validated genotype included
- **Data analysis**: dedicated software and workstation for automated data analysis

Assay performance:
115 samples with orthogonally validated genotype (Coriell, UK NEQAS, and clinical samples) have been used for the validation: 66 blood samples and 49 dry blood spot samples.

- **On target reads**: ≥ 99%
- **Clinical specificity**: 100%
- **Analytical sensitivity**: 1ng/reaction
- **Reproducibility (inter-assay variability)**: 100% of concordance
- **Repeatability (intra-assay variability)**: 100% of concordance

For information please contact:

Diatech Pharmacogenetics srl
Via Ignazio Silone 1b - 60035 Jesi (An) Italy - Tel. +39 0731 213 243
export@diatechpgx.com - www.diatechpharmacogenetics.com